Skip to Content

Silence Therapeutics PLC SLNCF

Morningstar Rating
$3.55 +0.30 (9.23%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SLNCF is trading at a 7% discount.
Price
$3.54
Fair Value
$6.49
Uncertainty
Very High
1-Star Price
$3.45
5-Star Price
$8.36
Economic Moat
Lkkm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLNCF is a good fit for your portfolio.

Trading Information

Previous Close Price
$3.25
Day Range
$3.553.55
52-Week Range
$0.603.55
Bid/Ask
$3.55 / $5.70
Market Cap
$411.83 Mil
Volume/Avg
500 / 850

Key Statistics

Price/Earnings (Normalized)
Price/Sales
7.94
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
122

Comparables

Valuation

Metric
SLNCF
ZURA
PRTA
Price/Earnings (Normalized)
Price/Book Value
2.702.37
Price/Sales
7.9410.07
Price/Cash Flow
Price/Earnings
SLNCF
ZURA
PRTA

Financial Strength

Metric
SLNCF
ZURA
PRTA
Quick Ratio
4.236.1110.97
Current Ratio
4.866.1511.24
Interest Coverage
−420.18
Quick Ratio
SLNCF
ZURA
PRTA

Profitability

Metric
SLNCF
ZURA
PRTA
Return on Assets (Normalized)
−28.81%−14.95%
Return on Equity (Normalized)
−18.32%
Return on Invested Capital (Normalized)
−122.50%−22.78%
Return on Assets
SLNCF
ZURA
PRTA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDzxd$552.7 Bil
VRTX
Vertex Pharmaceuticals IncXzskgqk$110.2 Bil
REGN
Regeneron Pharmaceuticals IncNhxmgs$105.9 Bil
MRNA
Moderna IncVpmg$37.9 Bil
ARGX
argenx SE ADRJxrjt$23.9 Bil
BNTX
BioNTech SE ADRVrhz$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncNnwtls$20.5 Bil
BMRN
Biomarin Pharmaceutical IncJbfxfc$16.9 Bil
RPRX
Royalty Pharma PLC Class ALnbcdf$13.9 Bil
INCY
Incyte CorpTgsvj$13.7 Bil

Sponsor Center